<DOC>
	<DOC>NCT00426803</DOC>
	<brief_summary>This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.</brief_summary>
	<brief_title>Recombinant Factor VIIa in Acute Intracerebral Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Spontaneous intracranial haemorrhage (ICH) within 3 hours after first symptom Patients with secondary ICH Preexisting disability Haemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>